January 25, 2016.
Big pharma leaders have warned against a British exit from the EU ("Brexit"), reports the Financial Times. At last week's World Economic Forum in Davos, Switzerland, GSK's Sir Andrew Witty pointed to the benefits that pan-European regulation has brought to the industry, stating “Europe has gone from 27 fragmented, independent, not-talking-to-each-each-other regulatory authorities in the healthcare space to one. That’s a big deal.” Eli Lilly head John Lechleiter has previously told the FT that it would be a “shame and a mistake” if Britain left the EU, while Dr Roger Perlmutter, head of R&D at Merck, said that Britain’s withdrawal from the EU would be “challenging” for its scientists, who had “benefited from a world where they receive grants from the EU". See Pharm Exec's EU correspondent Reflector's take on the issue here.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.